CA2408612A1 - Aqueous chondroprotective compositions having defined ph limitations for efficacious delivery - Google Patents

Abstract

The present invention is directed to compositions which are useful for promoting one or more health benefits including, for example, promoting joint health, bone health, cardiac health, and/or anti-inflammation. The present invention is further directed to kits comprising the compositions and methods of using the compositions and kits. In particular, the present invention is directed to compositions comprising: (a) a chondroprotective agent selected from the group consisting of aminosugars, aminosugar salts, and mixtures thereof; and (b) water; wherein the composition exhibits a pH from about 3 to about 5. The compositions are suitable for mammalian use. The invention also relates to kits comprising the present compositions and methods of administering to a mammal a composition as defined herein.

Description

AQUEOUS CHONDROPROTECTIVE COMPOSITIONS
HAVING DEFINED pH LIMITATIONS FOR EFFICACIOUS DELIVERY
FIELD OF THE INVENTION
The present invention is directed to ready-to-drink beverage compositions which are useful for promoting one or more health benefits including, for example, promoting joint health, bone health, cardiac health, and l or anti-inflammation. The present invention is further directed to kits comprising the compositions and methods of using the compositions and kits.
BACKGROUND OF THE INVENTION
Osteoarthritis is a widespread, degenerative disease of the joints, cartilage, and other articular components. Osteoarthritis affects all ethnic groups worldwide. In addition to humans, osteoarthritis affects nearly all mammals, for example, horses and cows, as well as domestic cats and dogs. Many treatments for osteoarthritis have been proposed, all resulting in varying degrees of success.
One osteoarthritis treatment which has been recently proposed is oral administration of chondroprotective agents such as glucosamine and / or chondroitin. See e.a., Henderson, U.S.
Patent No. 5,364,845, assigned to Nutramax Laboratories, issued November 15, 1994. Typically, administration of such agents is designed to enhance proteoglycan through an increased concentration of glycosaminoglycans. Enhanced proteoglycan provides the framework for collagen and other joint components, as well as imparting flexibility, resiliency, and resistance to compression. Thus, these agents may be administered according to various methods to enhance the articular compositions or, at a minimum, inhibit the process of degradation.
Unfortunately, it is well-known that glucosamine, and other similar agents, exhibit instability in the presence of aqueous solutions or even merely in the presence of hydrated atmosphere. As such, and not surprisingly, the bulk of the glucosamine-containing regimens are in dry form, e.g., pills and capsules. Some products may be provided in dry mix form, for formulation of chondroprotective beverage compositions in water immediately prior to consumption. This has limited the administration of glucosamine, and similar chondroprotective agents, to dry forms (e.g., pill form) or to dry mixes. These dry forms and mixes are particularly disadvantageous for several reasons. . For example, with respect to the dry forms, compliance is often an issue. Many consumers are adverse to incorporating pills into their daily regimen, particularly wherein multiple daily dosing is required with the currently available regimens (e.g., 500 mg of glucosamine, three times daily). Additionally, the available dry mixes are particularly unpalatable, which has a direct disadvantage with respect to compliance. As an even further disadvantage, dry mixes are not convenient and ready-to-use. Perhaps most importantly, dry mixes can introduce error in dosing the appropriate amount of chondroprotective agent (e.g., through improper reconstitution) and can potentially introduce contaminants into the final product.
However, the present inventors have discovered shelf-stable, ready-to-drink beverage compositions containing a chondroprotective agent such as glucosamine. The present inventors have surprisingly discovered that ready-to-drink beverage compositions containing a chondroprotective agent are feasible, even after long-term storage (e.g., two months or more), wherein the composition exhibits a pH of from about 3 to about 5. Thus, the present inventors overcome the previous stability issues associated with providing a ready-to-drink beverage. In doing so, the present inventors herein provide palatable, convenient chondroprotective compositions which encourage compliance with any particular regimen.
SUMMARY OF THE INVENTION
The present invention is directed to compositions which are useful for promoting one or more health benefits as defined herein. In particular, the present invention is directed to shelf-stable, ready-to-drink beverage compositions comprising:
(a) a chondroprotective agent selected from the group consisting of aminosugars, aminosugar salts, and mixtures thereof; and (b) water;
wherein the composition exhibits a pH from about 3 to about 5.
The products are suitable for mammalian use. The invention also relates to.
kits comprising the present compositions and information that use of the composition. promotes one or more of the presently defined health benefits, including joint health, bone health, cardiac health, and anti-inflammation. The present invention additionally relates to methods of treating joint function, bone function, cardiac function, or inflammation comprising administering to a mammal a composition as defined herein.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to shelf stable, ready-to-drink beverage compositions which are useful for promoting one or more health benefits. The compositions are suitable for mammalian use, particularly use in humans and domestic animals such as, for example, dogs, cats, horses, and cows. The present invention is further directed to kits comprising such compositions and methods of using such compositions.
The compositions of the present invention are useful for providing one or more joint health, bone health, cardiac health, and / or anti-inflammation benefits.
Joint health benefits include, but are not limited to, preventing, inhibiting, ceasing and l or reversing the actions associated with arthritis, particularly osteoarthritis. , Thus, improved joint health will provide, for example, decreased pain in the joints and increased flexibility. Bone health benefits include, but are not limited to, preventing, inhibiting, ceasing, and / or reversing bone loss and / or building bone mass, and / or preventing, inhibiting, ceasing, and / or reversing osteoporosis. Thus, improved bone health may provide, for example, healthy bones, stronger bones, and / or increased bone mass. Cardiac health benefits include, but are not limited to, preventing, inhibiting, ceasing, and / or reversing, for example, heart disease, atherosclerosis, and l or restenosis. Anti-inflammafiion benefits include, for example, preventing, inhibiting, ceasing, and /
or reversing inflammation, particularly in the joints. Thus, anti-inflammation will typically result in pain reduction.
Publications and patents are referred to throughout this disclosure. All references cited herein are hereby incorporated by reference.
All percentages and ratios are calculated by weight unless otherwise indicated. All percentages and ratios are calculated based on the total composition unless otherwise indicated.
All component or composition levels are in reference to the active level of that component or composition, and are exclusive of impurities, for example, residual solvents or by-products, which may be present in commercially available sources.
Referred to herein are trade names for components including various ingredients utilized in the present invention. The inventors herein do not intend to be limited by materials under a certain trade name. Equivalent materials (e.g., those obtained from a different source under a different name or catalog (reference) number) to those referenced by trade name may be substituted and utilized in the compositions, kits, and methods herein.
In the description of the invention various embodiments and / or individual features are disclosed. As will be apparent to the ordinarily skilled practitioner, all combinations of such embodiments and features are possible and can result in preferred executions of the present invention.
The compositions, kits, and methods herein may comprise, consist essentially of, or consist of any of the elements as described herein.
Ready-to-Drink Beverage Compositions of the Present Invention The present invention is directed to shelf-stable, ready-to-drink beverage compositions which are useful for promoting one or more health benefits which are described herein throughout in considerable detail. The compositions are suitable for mammalian use, particularly use in humans and domestic animals such as, for example, dogs, cats, horses, and cows. The present invention is further directed to kits comprising such compositions and methods of using such compositions.
Formulation of chondroprotective powder compositions in water immediately prior to consumption has historically been found important for preservation of stability, since it is well-known that glucosamine, and other similar components, exhibit instability in the presence of aqueous solutions or even merely in the presence of hydrated atmosphere.
Presumably, this has limited the administration of glucosamine, and similar chondroprotective agents, to dry forms (e.g., pill form) or to substantially dry mixes which are directed for dilution in water immediately prior to use. These dry forms and mixes are particularly disadvantageous for several reasons.
For example, with respect to the dry forms, compliance is often an issue. Many consumers are adverse to incorporating pills into their daily regimen, particularly wherein multiple daily dosing is required with the currently available regimens (e.g., 500 mg of glucosamine, three times daily).
Additionally, the available dry mixes are particularly unpalatable, which has a direct disadvantage with respect to compliance. As a further disadvantage, dry mixes are not convenient and ready-to-use.
The present inventors have surprisingly discovered that ready-to-drink beverage compositions containing glucosamine (and other similar chondroprotective agents) are feasible, even after long-term storage, wherein the composition exhibits a pH of from about 3 to about 5.
The present inventors have discovered that this mildly acidic matrix is critical for providing glucosamine stability. Preferably, the composition exhibits a pH of from about 3.5 to about 4.5, even more preferably from about 3.7 to about 4.2, and most preferably from about 3.7 to about 3.9. Thus, the present inventors provide convenient, palatable, and efficacious ready-to-drink beverage compositions comprising glucosamine, or a similar chondroprotective agent.
The Chondro~~rotective A4ent The chondroprotective agent utilized herein is selected from the group consisting of aminosugars, aminosugar salts, and mixtures thereof. The aminosugars are monosaccharide components (i.e., hexoses) which are modified with an amine functionality. The amine functionality may be a free amine moiety or a protected amine moiety (e.g., N-acetyl amine).
Preferably, the aminosugar is a precursor to glycosaminoglycan, which is important for construction of joint constituents (e.g., collagen). Additionally, certain aminosugars may serve to inhibit the activity of enzymes which are implicated in breakdown the cartilage in osteoarthritics (e.g., mannosamine, which has been discovered to inhibit aggrecanase). The aminosugars are well-known in the art; many aminosugars are naturally occurring.
As an example, glucosamine provides the building block needed in vivo to manufacture glycosaminoglycan, which is found in cartilage. Thus, glucosamine, and other aminosugars, function not only to relieve symptoms of joint pain but also stop, inhibit, and / or reverse the degenerative process.
Particularly preferred aminosugars include glucosamine, glucosamine salts, galactosamine, galactosamine salts, mannosamine, and mannosamine salts. More preferably, the aminosugars include glucosamine and salts of glucosamine, most preferably salts of glucosamine. Particularly preferred salts of glucosamine include glucosamine sulfate and glucosamine hydrochloride. The salts of glucosamine are particularly preferred to aid bioavailability and thus, efficacy.
Preferably, it has been discovered that the chondroprotective agent should be dosed, when intended for once-daily 'dosage, in a molar amount equivalent to at least about 1500 mg of glucosamine hydrochloride, based on dosing a human subject. Even more preferably, the chondroprotective agent should be dosed in a molar amount equivalent to from at least about 1800 mg of glucosamine hydrochloride, based on dosing a human subject. Still even more preferably, the chondroprotective agent should be dosed in a molar amount equivalent to from at least about 1800 mg to about 5000 mg of glucosamine hydrochloride, based on dosing a human subject. Most preferably, the chondroprotective agent should be dosed in a molar amount equivalent to from at least about 1800 mg to about 3600 mg of glucosamine hydrochloride, based on dosing a human subject.
Preferably, wherein the composition is intended for twice-daily dosage, the chondroprotective agent is dosed in a molar amount equivalent to at least about 850 mg, preferably, at least about 900 mg, of glucosamine hydrochloride, based on dosing a human subject. Also preferably, wherein the composition is intended for three-times-daily dosage, the chondroprotective agent is dosed in a molar amount equivalent to at least about 560 mg, preferably, at least about 590 mg, of glucosamine hydrochloride, based on dosing a human subject.
The foregoing preferred dosage levels are based on typical human subjects (e.g., about a 55 to 65 kg subject). Wherein the present composition is used in other mammals, it may be necessary to modify the dosage. Modification of dosages based on the needs of the subject is well within the skill of the ordinary artisan. It is therefore understood that these dosage ranges are by way of example only, and that daily administration can be adjusted depending on various factors. The specific dosage of the chondroprotective agent to be administered, as well as the duration of treatment are interdependent. The dosage and treatment regimen will also depend upon such factors as the specific chondroprotective agent used, the treatment indication, the efficacy of the compound, the personal attributes of the subject (such as, for example, weight, age, sex, and medical condition of the subject), and compliance with the treatment regimen.
Water Water is a necessary constituent of the present ready-to-drink compositions.
Wherein water is included within the compositions herein, the compositions preferably comprise at least about 20% water, more preferably at least about 40% water, still more preferably at least about 50% water, even more preferably at least about 75% water, and most preferably at least about 80% water. Still further, ready-to-drink beverage compositions will typically comprise from at least about 80% water to about 99.9% water. The water included at these levels includes all added water and any water present in combination components, for example, fruit juice.
In accordance with the present discovery, the ready-to-drink beverage compositions of the invention exhibit a pH of from about 3 to about 5. Preferably, the composition exhibits a pH of from about 3.5 to about 4.5, even more preferably from about 3.7 to about 4.2, and most preferably from about 3.7 to about 3.9.
If necessary, the present compositions may comprise one or more acidulants in order to reach, and maintain, the presently required pH. Beverage acidity can be adjusted to and maintained within the requisite range by known and conventional methods, e.g., the use of one or more acidulants.
Organic as well as inorganic edible acids may be used to adjust the pH of the ready-to-drink beverage compositions. The acids can be present in their undissociated form or, alternatively, as their respective salts, for example, potassium or sodium hydrogen phosphate, potassium or sodium dihydrogen phosphate salts. The preferred acids are edible organic acids which include citric acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid or mixtures thereof. The most preferred acids are citric and malic acids.
Optional Components of the Present Compositions Consistent with the present use as a ready-to-drink beverage, the compositions herein .
may comprise additional optional components to enhance, for example, their performance in providing joint health, bone health, other health benefits, a desirable nutritional profile, and / or organoleptic properties. For example, one or more "joint health agents" which differ from the chondroprotective agent described herein may be additionally utilized.
Further, one or more omega-3-fatty acids, bracers, flavanols, milk base solids, soluble fibers, non-caloric sweeteners, nutrients, flavoring agents, coloring agents, preservatives, emulsifiers, oils, carbonation components, and the like may be included in the compositions herein. Such optional components may be dispersed, solubilized, or otherwise mixed into the present compositions. These components may be added to the compositions herein provided they do not substantially hinder the properties of the beverage composition, particularly the provision of joint and / or bone health.
Non-limiting examples of optional components suitable for use herein are given below.
Further Joint Health Agents One or more "joint health agents" which, by definition herein, differ from the chondroprotective agent previously described, may optionally be used herein.
Such joint health agents will be well-known to one of ordinary skill in the art. Non-limiting examples of joint health agents include gelatin, cartilage, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts thereof, and mixtures thereof.
As is commonly known, gelatin is a protein obtained from the partial hydrolysis of collagen, which is the major structural and connective protein tissue in mammals. Gelatin typically contains from about 84% to about 90% protein, from about 1 % to about 2% mineral salts, and from about 8% to about 15% water (these are non-limiting approximations).
Gelatin typically contains specific amounts of 18 different amino acids, which are joined together to form polypeptide chains of approximately 1,000 amino acid residues per chain.
Typically, the collagen obtained for gelatin production is from animal bones and skins, e.g., from cows and pigs. Gelatin production will typically involve the subjection of collagenous material to alkaline pre-treatment, followed by hot-water extraction (providing gelatin having an iso-electric point of about 5). Acidic pre-treatment may also be utilized (providing gelatin having an iso-electric point of from about 7 to 9).
In accordance with the present invention, wherein gelatin is included within a present composition, a single dose of gelatin within the composition is preferably from about 1 mg to about 2000 mg, more preferably from about 7 00 mg to about 700 mg, even more preferably from about 150 mg to about 600 mg, and most preferably from about 200 mg to about 400 mg.
Typically, the composition comprising gelatin is dosed from about once to about five times daily.
However, in the food and beverage composition embodiments of the present invention, which are preferred, a typical dosage can be increased accordingly such that dosing need only occur about once daily. Thus, in these food and beverage compositions, compliance and consumer benefit is enhanced.
Cartilage may also be chosen for use in the present compositions, as a joint health agent .
additional to the chondroprotective agent used herein. As is commonly known in the art, cartilage is a tough, elastic tissue present in the joints (as well as other locations) of the bodies of various mammals. Cartilage is comprised of at least one of calcium, proteins, carbohydate mucopolysaccharides (e.g., chondroitin), and collagen.
Particularly preferred for use herein is bovine cartilage and shark cartilage.
Bovine cartilage is primarily derived from the trachea of cows (also known as bovine tracheal cartilage, or BTC). It is similar in structure to shark cartilage. Shark cartilage is a widely utilized cartilage source, as the skeletons of sharks are primarily composed of cartilage rather than bone.
In accordance with the present invention, wherein cartilage is included within a present composition, a single dose of cartilage within the composition is preferably from about 1 mg to about 2000 mg, more preferably from about 100 mg to about 700 mg, even more preferably from about 150 mg to about 600 mg, and most preferably from about 200 mg to about 400 mg.
Typically, the composition comprising cartilage is dosed from about once to about five times daily.
However, in the food and beverage composition embodiments of the present invention, which are preferred, a typical dosage can be increased accordingly such that dosing need only occur about once daily. Thus, in these food and beverage compositions, compliance and consumer benefit is enhanced.
One or more glycosaminoglycans may also optionally be utilized herein. The glycosaminoglycans are commonly known as GAGs, and are precursors to joint structure, for example, collagen. The glycosaminoglycans may also be important for the healing of bone.
Suitable gfycosaminoglycans will be well-known to the ordinarily skilled artisan. Preferred glycosaminoglycans include chondroitin, hyaluronic acid, keratan, heparin, and dermatin, as well as salts of the foregoing. For example, chondroitin sulfate is a particularly preferred chondroitin salt. As with the aminosugars, salts of the glycosaminoglycans are particularly preferred for use herein.
As an example, chondroitin provides the structure and allows various molecules to transport through cartilage (which is important, since there is no blood supply to cartilage).
Chondroitin is a major constituent of cartilage and' contains repeating chains of mucopolysaccharides.
Typical single dosing of the glycosaminoglycans is preferably from about 1 mg to about grams, more preferably from about 100 mg to about 5 grams, even more preferably from about 150 mg to about 1000 mg, and most preferably from about 250 mg to about 800 mg, based on the molecular weight of chondroitin. All other glycosaminoglycans may be similarly dosed, based on the molecular weight of chondroitin. Typically, the composition comprising the glycosaminoglycan is dosed from about once to about five times daily. However, in the food and beverage composition embodiments of the present invention, which are preferred, a typical dosage can be increased accordingly such that dosing need only occur about once daily.
The additional joint health agent may also be methylsufonylmethane, or a precursor thereof. As used herein, the term "precursor thereof' means a compound which, in mammalian systems, is converted to methylsulfonylmethane in vivo. Methylsulfonylmethane, and precursors thereof, are common ingredients found in vivo and in nature, e.g., in unprocessed foods. Without intending to be limited by theory, it is believed that the sulfur moiety present in methylsulfonylmethane, and its precursors, provides the disulfide bridging (also commonly known as "tie-bars" or "cross-links") necessary to hold the connective tissue in joints together.
While unprocessed foods contain methylsulfonylmethane, and the precursors thereof, conventional food processing and preparation causes the loss of these compounds from the foods. Therefore, commonly ingested foods may become deficient in these compounds. In these respects, methylsulfonylmethane is similar to vitamins and minerals which are typically partially or totally lost during normal food processing and preparation. It is therefore an important (but still optional) embodiment of this invention to include, methylsulfonylmethane or a precursor thereof in the present compositions.

Non-limiting examples of precursors of methylsulfonylmethane include methionine and methyl sulfide. See e.a., Herschler et al., U.S. Patent No. 4,863,748, issued September 5, 1989.
Precursors of methylsulfonylmethane is associated~with a variety of health benefits, including joint benefits (such as relief from osteoarthritis and rheumatoid arthritis), as well as anti-inflammation.
In accordance with the present invention, wherein methanesulfonylmethane is included within a present composition, a single dose of methanesulfonylmethane within the composition is preferably from about 0.01 mg to about 2000 mg, more preferably from about 0.01 mg to about 500 mg, even more preferably from about 1 mg to about 200 mg, and most preferably from about 1 mg to about 100 mg. The precursors of methanesulfonylmethane may be similarly dosed, based on the molecular weights of the precursors relative to methanesulfonylmethane. Typically, the composition comprising methanesulfonylmethane is dosed from about once to about five times daily. However, in the food and beverage composition embodiments of the present invention, which are preferred, a typical dosage can be increased accordingly such that dosing need only occur about once daily.
S-adenosylmethionine, which is commonly known as SAM-e, is a compound which is found in most, if not all, living cells. Without intending to be limited by theory, SAM-a is produced through reaction of the essential amino acid methionine and the energy molecule known as adenosine triphosphate (commonly known as ATP). SAM-a manufactures the components of cartilage and repairs, restores, and maintains joint function. SAM-a is made in vivo from the amino acid methionine, and is found in ordinary dietary sources such as meats, soybeans, eggs, seeds, and lentils.
In accordance with the present invention, wherein SAM-a is included within a present composition, a single dose of SAM-a within the composition is preferably from about 1 mg to about 2000 mg, more preferably from about 100 mg to about 700 mg, even more preferably from about 150 mg to about 600 mg, and most preferably from about 200 mg to about 400 mg.
Typically, the composition comprising SAM-a is dosed from about once to about five times daily.
However, in the food and beverage composition embodiments of the present invention, which are preferred, a typical dosage can be increased accordingly such that dosing need only occur about once daily.
As has been discussed previously in reference to the required chondroprotective agent herein, the foregoing dosage levels are based on typical human subjects (e.g., about a 55 to 65 kg subject). Wherein the present composition is used in other mammals, it may be necessary to modify the dosage. Modification of dosages based on the needs of the subject is well within the skill of the ordinary artisan. It therefore understood that these dosage ranges are by way of example only, and that daily administration can be adjusted depending on various factors.
The specific dosage of the chondroprotective agent to be administered, as well as the duration of treatment are interdependent. The dosage and treatment regimen will also depend upon such factors as the specific chondroprotective agent used, the treatment indication, the efficacy of the compound, the personal attributes of the subject (such as, for example, weight, age, sex, and medical condition of the subject), and compliance with the treatment regimen.
Omega-3-Fatty Acids In a particularly preferred embodiment of the present invention, one or more omega-3-fatty acids may be added to the present compositions. Omega-3-fatty acids are anti-inflammatory compounds which act as competitive inhibitors of the arachidonic acid cascade.
The omega-3-fatty acids are precursors to the synthesis of prostaglandins which function in mammals to regulate inflammation. See e. ., Burger, U.S. Patent No. 5,843,919, issued December 1, 1998.
The omega-3-fatty acid optionally utilized herein may be any omega-3-fatty acid or combination of omega-3-fatty acids. Non-limiting examples of omega-3-fatty acids which are suitable for use herein include eicosapentaenoic acid (also known as EPA), docosahexaenoic acid (also known as DHA), and mixtures thereof.
Optionally, the omega-3-fatty acid, as well as all other oil soluble components described herein, can be added to the present compositions via an emulsion and / or encapsulation.
Additionally, in essentially dry compositions, the omega-3-fatty acid may be spray dried according to commonly known techniques.
Wherein one or more omega-3-fatty acids is utilized in the present compositions, the ratio of the chondroprotective agent herein and the omega-3-fatty acids is often important for optimization of health benefits, particularly joint health benefits, bone health benefits, and anti-inflammation. Preferably, the ratio of the chondroprotective agent to the total omega-3-fatty acids) present in the composition (on a weight to weight basis) is from about 95:5 to about 5:95, more preferably from about 75:25 to about 25:75, most preferably from about 60:40 to about 40:60. The dosage of omega-3-fatty acids) included in the composition is therefore preferably administered according to these guidelines. Typical dosage levels of the chondroprotective agent have been detailed herein above.
Bracers As is commonly known in the art, bracers can be obtained by extraction from a natural source or can be synthetically produced. Non-limiting examples of bracers include methylxanthines, e.g., caffeine, theobromine, and theophylline. Additionally, numerous other xanthine derivatives have been isolated or synthesized, which may be utilized as a bracer in the compositions herein. See e.g., Bruns, Biochemical Pharmacology, Vol. 30, pp.
325 - 333 (1981) which describes, inter alia, xanthine, 9-methyl xanthine, 7-methyl xanthine, 3-methyl xanthine, 3,7-dimethyl xanthine, 8-chloromethyl-3,7-dimethyl xanthine, 8-hydroxymethyl-3,7-dimethyl xanthine, 3,7-diethyl xanthine, 3,7-bis-(2-hydroxyethyl) xanthine, 3-propyl-7-(dimethylaminoethyl) xanthine, 1-methyl xanthine, 1,9-dimethyl xanthine, 1-methyl-8-methylthio xanthine, 8-phenyl-1-methyl xanthine, 1,7-dimethyl xanthine, 1,7-dimethyl-8-oxo xanthine, 1,3-dimethyl xanthine, 1,3,9-trimethyl xanthine, 8-fluoro theophylline, 8-chloro theophylline, 8-bromo theophylline, 8-thio theophylline, 8-methylthio theophylline, 8-ethylthio theophylline, 8-nitro theophylline, 8-methylamino theophylline, 8-dimethylamino theophylline, 8-methyl theophylline, 8-ethyl theophylline, 8-propyl theophylline, 8-cyclopropyl theophylline, theophylline-8-propionate (ethyl ester), 8-benzyl theophylline, 8-cyclopentyl theophylline, 8-cyclohexyl theophylline, 8-(3-indolyl) theophylline, 8-phenyl theophylline, 9-methyl-8-phenyl theophylline, 8-(p-chlorophenyl) theophylline, 8-(p-bromophenyl) theophylline, 8-(p-methoxyphenyl) theophylline, 8-(p-nitrophenyl) theophylline, 8-(p-dimethylaminophenyl) theophylline, 8-(p-methylphenyl) theophylline, 8-(3,4-dichlorophenyl) theophylline, 8-(m-nitrophenyl) theophylline, 8-(o-nitrophenyl) theophylline, 8-(0-carboxyphenyl) theophylline, 8-(1-naphthyl) theophylline, 8-(2,6-dimethyl-4-hydroxyphenyl) theophylline, 7-methoxy-8-phenyl theophylline, 1,3,7-trimethyl xanthine, S-chloro caffeine, S-oxo caffeine, S-methoxy caffeine, S-methylamino caffeine, 8-diethylamino caffeine, 8-ethyl caffeine, 7-ethyl theophylline, 7-(2-chloroethyl) theophylline, 7-(2-hydroxyethyl) theophylline, 7-(carboxymethyl) theophylline, 7-(carboxymethyl) theophylline (ethyl ester), 7-(2-hydroxypropyl) theophylline, 7-(2,3-dihydroxypropyl) theophylline, 7-b-D-ribofuranosyl theophylline, 7-(glycero-pent-2-enopyranosyl) theophylline, 7-phenyl theophylline, 7,8-diphenyl theophylline, 1-methyl-3,7-diethyl xanthine, 1-methyl-3-isobutyl xanthine, 1-ethyl-3,7-dimethyl xanthine, 1,3-diethyl xanthine, 1,3,7-triethyl xanthine, 1-ethyl-3-propyl-7-butyl-8-methyl xanthine, 1,3-dipropyl xanthine, 1,3-diallyl xanthine, 1-butyl-3,7-dimethyl xanthine, 1-hexyl-3,7-dimethyl xanthine, and 1-(5-oxohexyl)-3,7-dimethyl xanthine.
Additionally, one or more of these bracers are present in, for example, coffee, flea, kola nut, cacao pod, mate', yaupon, guarana paste, and yoco. Natural plant extracts are the preferred sources of bracers as they may contain other compounds that delay the bioavailability of the bracer thus they may provide mental refreshment and alertness without tension or nervousness.
The most preferred methylxanthine is caffeine. Caffeine may be obtained from the aforementioned plants and their waste or, alternatively, may be synthetically prepared. Preferred botanical sources of caffeine which may be utilized as a complete or partial source of caffeine include green tea, guarana, mate', black tea, cola nuts, cocoa, and coffee. As used herein, green tea, guarana, coffee, and mate' are the most preferred botanical sources of caffeine, most preferably green tea, guarana, and coffee. Mate' may have the additional benefit of an appetite suppressing effect and may be included for this purpose as well. The total amount of caffeine, in any embodiment of the present invention, includes the amount of caffeine naturally present in the tea extract, flavoring agent, botanical and any other components, as well as any added caffeine.
Any bracer utilized herein is preferably present in physiologically relevant amounts, which means that the sources used in the practice of this invention provide a safe and effective quantity to achieve the desired mental alertness.

Wherein a bracer is utilized in the present compositions, such compositions will preferably comprise from about 0.0005% to about 1 %, more preferably from about 0.003% to about 0.5%, still more preferably from about 0.003% to about 0.2%, even more preferably from about 0.005% to about 0.05%, and most preferably from about 0.005% to about 0.02% of a bracer, by weight of the composition. Of course, as the skilled artisan will comprehend, the actual amount of bracer added will depend its biological effect, for example, effect of mental alertness on the consumer.
In all of the present compositions, the total amount of bracer includes any added bracer as well as any bracer naturally present in any other component of the present invention.
Flavanols Flavanols are natural substances present in a variety of plants (e.g., fruits, vegetables, and flowers). The flavanols which may be utilized in the present invention can be extracted from, for example, fruit, vegetables, green tea or other natural sources ,by any suitable method well known to those skilled in the art. For example, extraction with ethyl acetate or chlorinated organic solvents is a common method to isolate flavanols from green tea. Flavanols may be extracted from either a single plant or mixtures of plants. Many fruits, vegetables, and flowers contain flavanols but to a lesser degree relative to green tea. Plants containing flavanols are known to those skilled in the art. Examples of the most common flavanols which are extracted from tea plants and other members of the Catechu gambir (Uncaria family) include, for example, catechin, epicatechin, gallocatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate.
The flavanols utilized in all compositions of the present invention can be in the form of a tea extract. The tea extract can be obtained from the extraction of unfermented teas, fermented teas, partially fermented teas, and mixtures thereof. Preferably, the tea extracts are obtained from the extraction of unfermented and partially fermented teas. The most preferred tea extracts are obtained from green tea. Both hot and cold extracts can be used in the present invention.
Suitable methods for obtaining tea extracts are well known. See e.a., Ekanayake, U.S. Patent No.

5,879,733, issued March 9, 1999; Tsai, U.S. Patent No. 4,935,256, issued June, 1990; Lunder, U.S. 4,680,193, issued July, 1987; and Creswick, U.S. Patent No. 4,668,525, issued May 26, 1987.
The preferred source of flavanols in the compositions of the present invention is green tea. Wherein green tea, and in particular the flavanols present in green tea, are incorporated into the beverage, the present inventors have discovered that the flavanols are at least partially responsible for delaying the bioavailability of bracers, which contributes to the reduction and / or elimination of nervousness and tension typically associated with such bracers.
Alternatively, these same flavanols may be prepared by synthetic or other appropriate chemical methods and incorporated into the present compositions. Flavanols, including catechin, epicatechin, and their derivatives are commercially available.

The amount of flavanols in the compositions of the present invention can vary.
However, wherein one or more flavanols are utilized, preferably from about 0.001 % to about 5%, more preferably from about 0.001 % to about 2%, even more preferably from about 0.01 % to about 1 %, and most preferably from about 0.01 % to about 0.05% of one or more flavanols is utilized, by weight of the composition.
In all of the embodiments of the present invention, the total amount of flavanols includes any added flavanols as well as any flavanols naturally present in any other component of the present invention.
Milk Base Solids One or more milk base solids may also optionally be included in the compositions of the present invention. As used herein, milk base means milk from one or. more mammals or a plant-derived milk, and includes, for example, fermented milk, lactic acid beverages obtained by lactic acid fermentation or otherwise acidified, sterilized milk base, liquid milk, and milk products such as skim milk powder or whole milk powder or other powdered forms of milk. As used herein, milk base solids means the solids content or dry matter of milk base.
Wherein one or more milk base solids is utilized, the desired total level of milk base solids, calculated on a milk solids basis for the compositions of the present invention, is from about 0.001 % to about 15%, preferably from about 0.005% to about 10%, and most preferably from about 0.1 % to about 5%. The total amount of milk base solids includes any added milk base solid as well as any milk base solid naturally present in any other component of the present invention.
Soluble Fibers One or more soluble fibers may also optionally be included in the compositions of the present invention to provide, for example, nutritive benefits. Soluble fibers which can be used singularly or in combination in all embodiments of the present invention include but are not limited to pectins, psyllium, guar gum, xanthan gum, alginates, gum arabic, fructo-oligosaccharides, inulin, agar, and carrageenan. Preferred among these soluble fibers are at least one of guar gum, xanthan, and carrageenan, most preferably at least one of guar gum and xanthan. These soluble fibers may also serve as stabilizing agents in the various embodiments of this invention.
Particularly preferred soluble fibers for use herein are glucose polymers, preferably those which have branched chains. Preferred among these soluble fibers is one marketed under the trade name Fibersol2, commercially available from Matsutani Chemical Industry Co., Itami City, Hyogo, Japan.
Pectin and fructo-oligosaccharides are also preferred soluble fibers herein.
Even more preferably, pectin and fructo-oligosaccharides are used in combination. The preferred ratio of pectin to fructo-oligosaccharide is from about 3:1 to about 1:3, by weight of the composition. The preferred pectins have a degree of esterification higher than about 65%.

The preferred fructo-oligosaccharides are a mixture of fructo-oligosaccharides composed of a chain of fructose molecules linked to a molecule of sucrose. Most preferably, they have a nystose to kestose to fructosyl-nystose ratio of about 40:50:10, by weight of the composition.
Preferred fructo-oligosaccharides may be obtained by enzymatic action of fructosyltransferase on sucrose such as those which are, for example, commercially available from Beghin-Meiji Industries, Neuilly-sur-Seine, France.
Preferred pectins are obtained by hot acidic extraction from citrus peels and may be obtained, for example, from Danisco Co., Braband, Denmark.
Wherein a soluble fiber is utilized, the desired total level of soluble dietary fiber for the compositions of the present invention is from about 0.01 % to about 15%, preferably from about 0.1 % to about 5%, more preferably from about 0.1 % to about 3%, and most preferably from about 0.2% to about 2%, by weight of the composition. The total amount of soluble dietary fiber includes any added soluble dietary fiber as well as any soluble dietary fiber naturally present in any other component of the present invention.
Sweeteners The compositions of the present invention can, and typically will, contain an effective amount of one or more sweeteners, including carbohydrate sweeteners and natural and/or artificial no/low calorie sweeteners. The amount of the sweetener used in the beverages of the present invention typically depends upon the particular sweetener used and the sweetness intensity desired. For no/low calorie sweeteners, this amount varies depending upon the sweetness intensity of the particular sweetener.
The compositions of the present invention can be sweetened with any of the carbohydrate sweeteners, preferably monosaccharides and / or disaccharides.
Sweetened beverages will typically comprise from about 0.1 % to about 20%, most preferably from about 6 to about 14%, sweetener. These sugars can be incorporated into the beverages in solid or liquid form but are typically, and preferably, incorporated as a syrup, most preferably as a concentrated syrup such as high fructose corn syrup. For purposes of preparing beverages of the present invention, these sugar sweeteners can be provided to some extent by other components of the beverage such as, for example, the fruit juice component and / or flavors.
Preferred sugar sweeteners for use in beverage products of the present invention are sucrose, fructose, glucose, and mixtures thereof, particularly sucrose and fructose. Fructose can be obtained or provided as liquid fructose, high fructose corn syrup, dry fructose or fructose syrup, but is preferably provided as high fructose corn syrup. High fructose corn syrup (HFCS) is commercially available as HFCS-42, HFCS-55 and HFCS-90, which comprise 42%, 55% and 90%, respectively, by weight of the sugar solids therein, as fructose. Other naturally occurring sweeteners or their purified extracts, such as glycyrrhizin, stevioside, the protein sweetener thaumatin, the juice of Luo Han Guo (containing the sweet mogrosides) disclosed in, for example, Fischer et al., U. S. Patent No. 5,433,965, issued July 18, 1995, and the like can also be used in the beverages of the present invention.
Effective levels of non-caloric sweeteners may optionally be used in the compositions of the present invention to further sweeten such compositions. Non-limiting examples of non-caloric sweeteners include aspartame, saccharine, cyclamates, acesulfame K, L-aspartyl-L-phenylalanine lower alkyl ester sweeteners, L-aspartyl-D-alanine amides such as, for example, those disclosed in Brennan et al., U.S. Patent No. 4,411,925, issued 1983, L-aspartyl-D-serine amides such as, for example, those disclosed in Brennan et al., U.S. Patent No. 4,399,163, issued 1983, L-aspartyl-hydroxymethyl alkane amide sweeteners such as, for example, those disclosed in Brand, U.S. Patent No. 4,338,346, issued 1982, L-aspartyl-1-hydroxyethylalkane amide sweeteners such as, for example, those disclosed in Rizzi, U.S. Patent No. 4,423,029, issued 1983, glycyrrhizins, and synthetic alkoxy aromatics. Aspartame and acesulfame-K are the most preferred non-caloric sweeteners utilized herein, and may be utilized alone or in combination.
Wherein one or more sweeteners are utilized herein, the total non-caloric sweetener is preferably utilized at levels from about 0.0001 % to about 5%, more preferably from about 0.001 to about 3%, still more preferably from about 0.005% to about 2%, even more preferably from about 0.01 % to about 1 %, and most preferably from about 0.01 % to about 0.05%, by weight of the composition.
Nutrients The compositions herein may optionally, but preferably, be fortified further with one or more nutrients, especially one or more vitamins and / or minerals. The U.S.
Recommended Daily Intake (USRDI) for vitamins and minerals are defined and set forth in the Recommended Daily Dietary Allowance-Food and Nutrition Board, National Academy of Sciences-National Research Council.
Unless otherwise specified herein, wherein a given mineral is present in the composition, the composition typically comprises at least about 1 %, preferably at least about 5%, more preferably from about 10% to about 200%, even more preferably from about 40%
to about 150%, and most preferably from about 60% to about 125% of the USRDI of such mineral.
Unless otherwise specified herein, wherein a given mineral is present in the composition, the composition comprises at least about 1 %, preferably at least about 5%, more preferably from about 10% to about 200%, even more preferably from about 20% to about 150%, and most preferably from about 25% to about 120% of the USRDI of such vitamin.
Non-limiting examples of such further vitamins and minerals, include niacin, thiamin, folic acid, pantothenic acid, biotin, vitamin A, vitamin C, vitamin Bz, vitamin B3, vitamin B6, vitamin B~~, vitamin D, vitamin E, vitamin K, iron, zinc, copper, phosphorous, iodine, chromium, molybdenum, and fluoride. Preferably, wherein a further vitamin or mineral is utilized the vitamin or mineral is selected from niacin, thiamin, folic acid, iodine, vitamin A, vitamin C, vitamin B6, vitamin BIZ, vitamin D, vitamin E, iron, zinc, and calcium. Preferably, at least one vitamin is selected from vitamin C, vitamin B6, vitamin B~2, vitamin E, pantothenic acid, niacin, and biotin. Also preferably, the composition comprises vitamin C and one or more other vitamins selected from vitamin B6, vitamin B~2, vitamin E, pantothenic acid, niacin, and biotin.
Commercially available vitamin A sources may also be included in the present compositions. As used herein, "vitamin A" includes, but is not limited to, vitamin A (retinol), a-carotene, retinol palmitate, and retinol acetate. The vitamin A may be in any form, for example, an oil, beadlets, or encapsulated. Wherein vitamin A is present in the compositions herein, the product comprises at least about 1 %, preferably at least about 5%, more preferably from about 10% to about 200%, even more preferably from about 15% to about 150%, and most preferably from about 20% to about 120% of the USRDI of such vitamin. Wherein vitamin A
is present in the compositions herein, it is especially preferred to include about 25% of the USRDI of vitamin A.
The quantity of vitamin A to be added is dependent on processing conditions and the amount of vitamin A deliver desired after storage. Preferably, wherein vitamin A is included within the present compositions, the compositions comprise from about 0.0001 % to about 0.2%, more preferably from about 0.0002% to about 0.12%, also preferably from about 0.0003% to about 0.1 %, even more preferably from about 0.0005% to about 0.08%, and most preferably from about 0.001 % to about 0.06% of vitamin A, by weight of the product.
Commercially available sources of vitamin B2 (also known as riboflavin) may be utilized in the present compositions. Wherein vitamin B2 is present in the compositions herein, the product comprises at least about 1 %, preferably at least about 5%, more preferably from about 5% to about 200%, even more preferably from about 10% to about 150%, and most preferably from about 10% to about 120% of the USRDI of such vitamin. Wherein vitamin B2 is present in the compositions herein, it is especially preferred to include from about 15%
to about 35% of the USRDI of vitamin B2.
Vitamin C (ascorbic acid) is a particularly preferred optional ingredient for use herein.
Without intending to be limited by theory, it is believed that vitamin C may be utilized to enhance the benefits herein, by serving as a co-factor for the enzyme which cross-links collagen.
Encapsulated ascorbic acid and edible salts of ascorbic acid can also be used.
Wherein vitamin C is present in the compositions herein, the product comprises at least about 1 %, preferably at least about 5%, more preferably from about 10% to about 200%, even more preferably from about 20% to about 150%, and most preferably from about 25% to about 120% of the USRDI of such vitamin. Wherein vitamin C is present in the compositions herein, it is especially preferred to include about 100% of the USRDI of vitamin C. The quantity of vitamin C
to be added is dependent on processing conditions and the amount of vitamin C
deliver desired after storage. Preferably, wherein vitamin C is included within the present compositions, the compositions comprise from about 0.005% to about 0.2%, more preferably from about 0.01 % to about 0.12%, also preferably from about 0.02% to about 0.1 %, even more preferably from about 0.02% to about 0.08%, and most preferably from about 0.03% to about 0.06% of vitamin C, by weight of the product.
Nutritionally supplemental amounts of other vitamins which may be incorporated herein include, but are not limited to, vitamins B6 and B12, folic acid, niacin, pantothenic acid, folic acid, vitamin D, and vitamin E. Wherein the product comprises one of these vitamins, the product preferably comprises at least 5%, preferably at least 25%, and most preferably at least 35% of the USRDI for such vitamin.
Minerals which may optionally be included in the compositions herein are, for example, calcium, manganese, magnesium, boron, zinc, iodine, iron, and copper. Minerals may be, for example, salts, chelated, complexed, or in colloidal form.
Any soluble salt of these minerals suitable for inclusion edible compositions can be used, for example, magnesium citrate, magnesium gluconate, magnesium sulfate, zinc chloride, zinc sulfate, potassium iodide, copper sulfate, copper gluconate, and copper citrate.
Manganese is a particularly preferred mineral for use herein, as this mineral is involved in the synthesis of glycosaminoglycans, collagen, and glycoproteins. Additionally manganese deficiencies can lead to abnormal bone growth, inflamed joints, bone loss, and arthritis.
Manganese ascorbate is a particularly preferred form of manganese for use herein. Typical manganese dosages range from about 0 mg to about 1000 mg, more preferably from about 50 mg to about 950 mg, and most preferably from about 50 mg to about 250 mg for a human or large mammal (e.g., horse).
Boron is a particularly preferred mineral for use herein, as this mineral is necessary for osteocalcin formation in bone.
Calcium is a particularly preferred mineral for use in the present invention.
Preferred sources of calcium include, for example, amino acid chelated calcium, calcium carbonate, calcium oxide, calcium hydroxide, calcium sulfate, calcium chloride, calcium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate, calcium citrate, calcium malate, calcium titrate, calcium gluconate, calcium realate, calcium tantrate, and calcium lactate, and in particular calcium citrate-malate. The form of calcium citrate-malate is described in, e.g., Mehansho et al., U.S. Patent No. 5,670,344, issued September 23, 1997; Diehl et al., U.S.
Patent No. 5,612,026, issued March 18, 1997; Andon et al., U.S. Patent No. 5,571,441, issued November 5, 1996;
Meyer et al., U.S. Patent No. 5,474,793, issued December 12, 1995; Andon et al., U.S. Patent No. 5,468,506, issued November 21, 1995; Burkes et al., U.S. Patent No.
5,445,837, issued August 29, 1995; Dake et al., U.S. Patent No. 5,424,082, issued June 13, 1995;
Burkes et al., U.S. Patent No. 5,422,128, issued June 6, 1995; Burkes et al., U.S. Patent No.
5,401,524, issued March 28, 1995; Zuniaa et al., U.S. Patent No. 5,389,387, issued February 14, 1995; Jacobs, U.S. Patent No. 5,314,919, issued May 24, 1994; Saltman et al., U.S. Patent No. 5,232,709, issued August 3; 1993; Camden et al., U.S. Patent No. 5,225,221, issued July 6, 1993; Fox et al., U.S. Patent No. 5,215,769, issued June 1, 1993; Fox et al., U.S. Patent No.
5,186,965, issued February 16, 1993; Saltman et al., U.S. Patent No. 5,151,274, issued September 29, 1992;
Kochanowski, U.S. Patent No. 5,128,374, issued July 7, 1992; Mehansho et al., U.S. Patent No.
5,118,513, issued June 2, 1992; Andon et al., U.S. Patent No. 5,108,761, issued April 28, 1992;
Mehansho et al., U.S. Patent No. 4,994,283, issued February 19, 1991; Nakel et al., U.S. Patent No. 4,786,510, issued November 22, 1988; and Nakel et al., U.S. Patent No.
4,737,375, issued April 12, 1988. Preferred compositions of the present invention will comprise from about 0.01 % to about 0.5%, more preferably from about 0.03% to about 0.2%, even more preferably from about 0.05% to about 0.15%, and most preferably from about 0.1 % to about 0.15% of calcium, by weight of the product.
Iron may also be utilized in the compositions and methods of the present invention.
Acceptable forms of iron are well-known in the art. The amount of iron compound incorporated into the product will vary widely depending upon the level of supplementation desired in the final product and the targeted consumer. Iron fortified compositions of the present invention typically contain from about 5% to about 100%, preferably from about 15% to about 50%, and most preferably about 20% to about 40% of the USRDI for iron.
Ferrous iron is typically better utilized by the body than ferric iron. Highly bioavailable ferrous salts that can be used in the ingestible compositions of the present invention are ferrous sulfate, ferrous fumarate, ferrous succinate, ferrous gluconate, ferrous lactate, ferrous tartarate, ferrous citrate, ferrous amino acid chelates, as well as mixtures of these ferrous salts. While ferrous iron is typically more bioavailable, certain ferric salts can also provide highly bioavailable sources of iron. Highly bioavailable ferric salts that can be used in the food or beverage compositions of the present invention are ferric saccharate, ferric ammonium citrate, ferric citrate, ferric sulfate, as well as mixtures of these ferric salts. Combinations or mixtures of highly bioavailable ferrous and ferric salts can be used in these edible mixes and ready-to-serve beverages. The preferred sources of highly bioavailable iron are ferrous fumarate and ferrous amino acid chelates.
Ferrous amino acid chelates particularly suitable as highly bioavailable iron sources for use in the present invention are those having a ligand to metal ratio of at least 2:1. For example, suitable ferrous amino acid chelates having a ligand to metal mole ratio of two are those of formula:
Fe(L)2 where L is an alpha amino acid, dipeptide, tripeptide, or quadrapeptide ligand. Thus, L can be any ligand which is a naturally occurring alpha amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamine, glutamic acid, glycine, histidine, hydroxyproline, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; or dipeptides, tripeptides, or quadrapeptides formed by any combination of these alpha amino acids. See e.a., Ashmead et al., U.S.
Patent No.
4,863,898, issued September 5, 1989; Ashmead, U.S. Patent No. 4,830,716, issued May 16, 1989; and Ashmead, U.S. Patent No. 4,599,152, issued July 8, 1986, all of which are incorporated by reference. Particularly preferred ferrous amino acid chelates are those where the reacting ligands are glycine, lysine, and leucine. Most preferred is the ferrous amino acid chelate sold under the mark Ferrochel° (Albion Laboratories, Salt Lake City, Utah) wherein the ligand is glycine.
In addition to these highly bioavailable ferrous and ferric salts, other sources of bioavailable iron can be included in the food and beverage compositions of the present invention.
Other sources of iron particularly suitable for fortifying compositions of the present invention included certain iron-sugar-carboxylate complexes. In these iron-sugar-carboxylate complexes, the carboxylate provides the counterion for the ferrous (preferred) or ferric iron. The overall synthesis of these iron-sugar-carboxylate complexes involves the formation of a calcium-sugar moiety in aqueous media (for example, by reacting calcium hydroxide with a sugar, reacting the iron source (such as ferrous ammonium sulfate) with the calcium-sugar moiety in aqueous media to provide an iron-sugar moiety, and neutralizing the reaction system with a carboxylic acid (the "carboxylate counterion") to provide the desired iron-sugar- carboxylate complex. Sugars that can be used to prepare the calcium-sugar moiety include any of the ingestible saccharidic materials, and mixtures thereof, such as glucose, sucrose and fructose, mannose, galactose, lactose, maltose, and the like, with sucrose and fructose being the more preferred. The carboxylic acid providing the "carboxylate counterion" can be any ingestible carboxylic acid such as citric acid, malic acid tartaric acid, lactic acid, succinic acid, propionic acid, etc., as well as mixtures of these acids.
These iron-sugar-carboxylate complexes can be prepared in the manner described in, e.g., Nakel et al., U.S. Patent Nos. 4,786,510 and 4,786,518, issued November 22, 1988, both of which are incorporated by reference. These materials are referred to as "complexes", but they may exist in solution as complicated, highly hydrated, protected colloids; the term "complex" is used for the purpose of simplicity.
Zinc may also be utilized in the compositions and methods of the present invention.
Acceptable forms of zinc are well-known in the art. Zinc fortified compositions of the present invention typically contain from about 5% to about 100%, preferably from about 15% to about 50%, and most preferably about 25% to about 45% of the USRDI for zinc. The zinc compounds which can be used in the present invention can be in any of the commonly used forms such as, e.g., zinc sulfate, zinc chloride, zinc acetate, zinc gluconate, zinc ascorbate, zinc citrate, zinc aspartate, zinc picolinate, amino acid chelated zinc, and zinc oxide. Zinc gluconate and amino acid chelated zinc are particularly preferred.
Flavoring Agents One or more flavoring agents are recommended for the embodiments of the present invention in order to enhance their palatability. Any natural or synthetic flavor agent can be used in the present invention. For example, one or more botanical and / or fruit flavors may be utilized herein. As used herein, such flavors may be synthetic or natural flavors.
Particularly preferred fruit flavors are exotic and lactonic flavors such as, for example, passion fruit flavors, mango flavors, pineapple flavors, cupuacu flavors, guava flavors, cocoa flavors, papaya flavors, peach flavors, and apricot flavors. Besides these flavors, a variety of other fruit flavors can be utilized such as, for example, apple flavors, citrus flavors, grape flavors, raspberry flavors, cranberry flavors, cherry flavors, grapefruit flavors, and the like. These fruit flavors can be derived from natural sources such as fruit juices and flavor oils, or may alternatively be synthetically prepared.
Preferred botanical flavors include, for example, tea (preferably black and green tea, most preferably green tea), aloe vera, guarana, ginseng, ginkgo, hawthorn, hibiscus, rose hips, chamomile, peppermint, fennel, ginger, licorice, lotus seed, schizandra, saw palmetto, sarsaparilla, safflower, St. John's Wort, curcuma, cardimom, nutmeg, cassia bark, buchu, cinnamon, jasmine, haw, chrysanthemum, water chestnut, sugar cane, lychee, bamboo shoots, vanilla, coffee, and the like. Preferred among these is tea, guarana, ginseng, ginko, and coffee.
In particular, the combination of tea flavors, preferably green tea or black tea flavors (preferably green tea), optionally together with fruit flavors has an appealing taste. In another preferred embodiment, coffee is included within the present compositions. A combination of green tea and coffee in the present compositions is often preferred.
The flavor agent can also comprise a blend of various flavors. If desired, the flavor in the flavoring agent may be formed into emulsion droplets which are then dispersed in the beverage composition or concentrate. Because these droplets usually have a specific gravity less than that of water and would therefore form a separate phase, weighting agents (which can also act as clouding agents) can be used to keep the emulsion droplets dispersed in the beverage composition or concentrate. Examples of such weighting agents are brominated vegetable oils (BVO) and resin esters, in particular the ester gums. See L.F. Green, Developments in Soft Drinks Technology, Vol. 1, Applied Science Publishers Ltd., pp. 87-93 (1978) for a further description of the use of weighting and clouding agents in liquid beverages.
Typically the flavoring agents are conventionally available as concentrates or extracts or in the form of synthetically produced flavoring esters, alcohols, aldehydes, terpenes, sesquiterpenes, and the like.
Coloring Agent Small amounts of one or more coloring agents may be utilized in the compositions of the present invention. FD&C dyes (e.g., yellow #5, blue #2, red # 40) and / or FD&C lakes are preferably used. By adding the lakes to the other powdered ingredients, all the particles, in particular the colored iron compound, are completely and uniformly colored and a uniformly colored beverage mix is attained. Preferred lake dyes which may be used in the present invention are the FDA-approved Lake, such as Lake red #40, yellow #6, blue #1, and the like.
Additionally, a mixture of FD&C dyes or a FD&C lake dye in combination with other conventional food and food colorants may be used. Riboflavin and b-carotene may also be used. Additionally, other natural coloring agents may be utilized including, for example, fruit, vegetable, and / or plant extracts such as grape, black currant, aronia, carrot, beetroot, red cabbage, and hibiscus.
The amount of coloring agent used will vary, depending on the agents used and the intensity desired in the finished product. The amount can be readily determined by one skilled in the art. Generally, if utilized, the coloring agent should be present at a level of from about 0.0001 % to about 0.5%, preferably from about 0.001 % to about 0.1 %, and most preferably from about 0.004% to about 0.1 %, by weight of the composition.
Preservatives Optionally, one or more preservatives may additionally be utilized herein.
Preferred preservatives include, for example, sorbate, benzoate, and polyphosphate preservatives.
Preferably, wherein a preservative is utilized herein, one or more sorbate or benzoate preservatives (or mixtures thereof) are utilized. Sorbate and benzoate preservatives suitable for use in the present invention include sorbic acid, benzoic acid, and salts thereof, including (but not limited to) calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, and mixtures thereof. Sorbate preservatives are particularly preferred. Potassium sorbate is particularly preferred for use in the present invention.
.Wherein a composition comprises a preservative, the preservative is preferably included at levels from about 0.0005% to about 0.5%, more preferably from about 0.001 %
to about 0.4% of the preservative, still more preferably from about 0.001 % to about 0.1 %, even more preferably from about 0.001 % to about 0.05%, and most preferably from about 0.003% to about 0.03% of the preservative, by weight of the composition. Wherein the composition comprises a mixture of one or more preservatives, the total concentration of such preservatives is preferably maintained within these ranges.
Emulsifiers and Oils One or more emulsifiers and / or oils may also be included in the present compositions for texture and opacity purposes. Typical emulsifiers and oils useful herein include, for example, mono-di glycerides, lecithin, pulp, cotton seed oil, and vegetable oil.
Carbonation Component Carbon dioxide can be introduced into the water which is mixed with a beverage concentrate or into the beverage composition after dilution to achieve carbonation. The carbonated beverage can be placed into a container, such as a bottle or can, and then sealed.
Any conventional carbonation methodology may be utilized to make carbonated beverage compositions of this invention. The amount of carbon dioxide introduced into the beverage will depend upon the particular flavor system utilized and the amount of carbonation desired.
Kits of the Present Invention The present invention further relates to kits comprising the foregoing compositions and information that use of the composition promotes a benefit selected from the group consisting. of joint health, bone health, cardiac health, anti-inflammation, refreshment, and nutrition.
The kits of the present invention may comprise one or more compositions together with information which informs a user of the kit, by words, pictures, and / or the like, that use of the kit will provide one or more general health and / or general physiological benefits including, but not limited to, joint health benefits (including relief from, prevention of, and /
or inhibition of, arthritis and / or osteoarthritis, as well as enhanced flexibility), bone health benefits (including maintaining and / or building bones), cardiac health, anti-inflammation (e.g., pain relief), refreshment, and nutrition (including specific nutritional benefits). Such information need not utilize the actual words used herein, for example, "joint", "bone", "cardiac", or "nutrition", but rather use of words, pictures, symbols, and the like conveying the same or similar meaning are contemplated within the scope of this invention.
In a particularly preferred embodiment, the information is printed on a container holding the composition, e.g., a bottle. These preferred kits may be in the form of one bottle containing the composition, or may be obtained as a plurality of bottles each containing the composition. For example, the kits may be obtained as one bottle, or cases of four, six, seven (e.g., a weekly supply), or eight bottles co-packaged together. Additionally, monthly kits may be obtained as cases of, for example, twenty-eight or thirty bottles co-packaged together.
Methods of the Present Invention The methods of the present invention comprise orally administering (i.e., through ingestion) a composition of the present invention to a mammal, preferably a human, to provide various health benefits, including joint, bone, cardiac, and anti-inflammation benefits, as well as nutritive and organoleptic benefits. The compositions of the present invention are most preferably ingested by consumers desiring a palatable composition, a means to satisfy between-meal hunger, or as a substitute for ingesting a pill-form or mixing a dry mix with water, such to increase compliance. The compositions are also preferably ingested by consumers who experience joint and l or bone dysfunction or those who desire to maintain current joint and /
or bone function (i.e., prophylactic use). The compositions of this invention may also be ingested as a supplement to normal dietetic requirements. Frequency of administration is not limited, however, such administration is typically at least once weekly, more preferably at least 3 times weekly, and most preferably at least once daily.
As used herein, the term "orally administering" with respect to the mammal (preferably, human or domestic animal such as a horse, cow, cat, or dog (most preferably a human)) means that the mammal ingests or is directed to ingest (preferably, for the purpose of providing joint and / or bone health) one or more ready-to-drink beverage compositions of the present invention.
Wherein the mammal is directed to ingest one or more of the compositions, such direction may be that which instructs and / or informs the user that use of the composition may and / or will provide one or more general health and / or general physiological benefits including, but not limited to, joint health, bone health, cardiac health, anti-inflammation, refreshment, satiation, and nutrition.
For example, such direction may be oral direction (e.g., through oral instruction from, for example, a physician, health professional, sales professional or organization, and / or radio or television media (i.e., advertisement) or written direction (e.g., through written direction from, for example, a physician or other health professional (e.g., scripts), sales professional or organization (e.g., through, for example, marketing brochures, pamphlets, or other instructive paraphernalia), written media (e.g., Internet, electronic mail, or other computer-related media), and I or packaging associated with the composition (e.g., a label present on a package containing the composition).
As used herein, "written" means through words, pictures, symbols, and / or other visible descriptors. Such direction need not utilize the actual words used herein, for example, "joint", "bone", "human", or "mammal", but rather use of words, pictures, symbols, and the like conveying the same or similar meaning are contemplated within the scope of this invention.
Methods of Making The presently described ready-to-drink beverage compositions are made according to methods which will be well known by the ordinarily skilled artisan. To illustrate, the compositions of the present invention may be prepared by dissolving, dispersing, or otherwise mixing all components singularly or in suitable combinations together and in water where appropriate, agitating with a mechanical stirrer until all of the ingredients have been solubilized or adequately dispersed. Where appropriate, all separate solutions and dispersed may then be combined.
When using the present chondroprotective agents which have been discovered to be pH sensitive as described herein, it may be important to adjust the desired pH with an acidulant and / or buffer system before adding the chondroprotective agent to the mixture. Wherein a shelf stable composition is desired, the final mixture can optionally, but preferably, be pasteurized or filled aseptically at appropriate process conditions.

In making a beverage composition, a beverage concentrate may optionally be formed first. One method to prepare the concentrate form of the beverage composition would be to start with less than the required volume of water that is used in the preparation of the beverage composition. Another method would be to partially dehydrate the finally prepared beverage compositions to remove only a portion of the water and any other volatile liquids present.
Dehydration may be accomplished in accordance with well known procedures, such as evaporation under vacuum. The concentrate can be in the form of a relatively thick liquid. A
syrup is typically formed by adding suitable ingredients such as electrolytes or emulsions to the beverage concentrate. The syrup is then mixed with water to form a finished beverage or finished beverage concentrate. The weight ratio of water to syrup is typically from about 1:1 to about 5:1.
Carbon dioxide can be introduced either into the water to be mixed with the beverage concentrate, or into the ready-to-drink beverage composition, to achieve carbonation. The carbonated beverage composition can then be stored in a suitable container and then sealed.
Techniques for making and carbonating beverage embodiments of the present invention are described in the following references: L.F. Green (ed.), Developments in Soft Drinks Technology, Vol. 1 (Elsevier, 1978); G.S. Cattell and P.M. Davies, "Preparation and Processing of Fruit Juices, Cordials and Drinks", Journal of the Society of Dairy Technology; Vol. 38 (1 ), pp. 21-27, A.H.
Varnam and J.P. Sutherland, Beverages - Technology, Chemistry and Microbiology, Chapman Hall, 1994; and A.J. Mitchell (ed.), Formulation and Production of Carbonated Soft Drinks, Blackie and Sons Ltd., 1990.
EXAMPLES
The following are non-limiting examples of the present compositions which are prepared utilizing conventional methods. The following examples are provided to illustrate the invention and are not intended to limit the scope thereof in any manner.
Example 1 An 8 oz. ready-to-drink beverage composition is prepared by combining the following components in a conventional manner:
Component Wt%

Glucosamine Hydrochloride 0.8 Fructose 9.3 Thickeners 0.04 Calcium citrate malate 0.67 Fruit Juice Concentrate 1.65 Natural Flavors 0.02 Ascorbic Acid 0.04 Citric Acid 0.35 Water quantum satis In a particularly preferred example of this beverage composition, approximately 1800 mg of the glucosamine hydrochloride is used in the composition. If needed, the pH of the beverage composition is adjusted to around 3.7. Various flavors of the beverage composition may be formulated according to standard techniques, for example, grapefruit and / or cranberry flavors.
Example 2 A kit comprising the ready-to-drink beverage composition of Example 1 and information describing the benefits of consuming the beverage composition is prepared. The beverage composition is contained within a glass bottle containing language such as "Improves Flexibility", "Excellent Source of Calcium", and / or the like. The kit is obtained by a 50-year-old female human and is orally ingested by the female human.
Example 3 A 4 oz. ready-to-drink beverage composition is prepared by combining the following components in a conventional manner:
Component Wt%

Glucosamine Hydrochloride 1.6 Chondroitin Sulfate 2.0 Fructose 9.3 Thickeners 0.04 Calcium citrate malate 1.14 Fruit Juice Concentrate 1.65 Natural Flavors 0.02 Ascorbic Acid 0.08 Citric Acid 0.35 Water quantum satis If needed, the pH of.the beverage composition is adjusted to from about 3.7 to about 3.9. Various flavors of the beverage composition may be formulated according to standard techniques, for example, grapefruit and / or cranberry flavors. If desired, this beverage composition may be further diluted by the consumer prior to ingestion with additional water, or a beverage of the consumer's choice.

Example 4 A kit comprising the ready-to-drink beverage composition of Example 3 and information describing the benefits of consuming the beverage composition is prepared. The beverage composition is contained within a glass bottle containing language such as "Relieves Joint Pain", "Excellent Source of Calcium", and / or the like. The kit is obtained by a 45-year-old female human and is orally ingested by the female human.
Example 5 A 2 oz. ready-to-drink beverage composition is prepared by combining the following components in a conventional manner:
Component Wt%

Glucosamine Hydrochloride 3.2 Fructose 9.3 Thickeners 0.04 Calcium citrate malate 2.3 Fruit Juice Concentrate 1.65 Natural Flavors 0.02 Ascorbic Acid 0.16 Citric Acid 0.35 Water quanfum satis If needed, the pH of the beverage composition is adjusted to from about 3.7 to about 3.9. Various flavors of the beverage composition may be formulated according to standard techniques, for example, grapefruit and / or cranberry flavors. Preferably, this beverage composition may be further diluted by the consumer prior to ingestion with additional water, or a beverage of the consumer's choice.
Example 6 A kit comprising the beverage composition of Example 5 and information describing the benefits of consuming the beverage composition is prepared. The beverage composition is contained within a glass bottle containing language such as "Improves Flexibility", "Excellent Source of Calcium", and l or the like. The kit is obtained by an athletic 25-year-old female human and is orally ingested by the female human.

Claims (10)

WHAT IS CLAIMED IS:

1. A ready-to-drink beverage composition characterized by:
(a) a chondroprotective agent selected from the group consisting of aminosugars, aminosugar salts, and mixtures thereof; and (b) water;
wherein the composition is further characterized by a pH from about 3 to about 5.

2. A composition according to Claim 1 wherein the chondroprotective agent is selected from the group consisting of glucosamine, glucosamine salts, galactosamine, galactosamine salts, mannosamine, and mannosamine salts.

3. A composition according to any of the preceding claims which is characterized by a pH from about 3.5 to about 4.5.

4. A composition according to any of the preceding claims wherein the chondroprotective agent is selected from the group consisting of glucosamine and glucosamine salts.

5. A composition according to any of the preceding claims which is characterized by at least about 50% water.

6. A composition according to any of the preceding claims wherein the chondroprotective agent is selected from the group consisting of glucosamine sulfate and glucosamine hydrochloride.

7. A composition according to any of the preceding claims which is characterized by a pH from about 3.7 to about 4.2.

8. A composition according to any of the preceding claims which is characterized by a pH from about 3.7 to about 3.9.

9. A composition according to any of the preceding claims which is further characterized by one or more beverage components selected from the group consisting of fruit juice, tea solids, milk solids, fruit flavors, botanical flavors, and mixtures thereof.

10. A composition according to any of the preceding claims which is further characterized by one or more nutrients.